Phase II Study of SHJ002 Sterile Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

Summary

The purpose of this study is to measure efficacy and safety with SHJ002 sterile ophthalmic solution compared to vehicle in participants with Dry Eye Disease (DED). SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.

Timeline

Start

2023-02-08

Primary completion

2023-12-07

Completion

2023-12-07

Publications

• Kasetsuwan N, Jaross N, Reinprayoon U, Daruwalla Z, Choo J, Liang YH, Juo SH, Liang CL. Assessing the Efficacy, Safety Profile, and Tolerability of Anti-microRNA-328 Anti-sense (SHJ002) for Dry Eye Disease: A Randomized Phase 2 Trial. Clin Ther. 2026 Jun;48(6):525-529. doi: 10.1016/j.clinthera.2026.03.023. Epub 2026 Apr 25.

Drugs

Indications